跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
LAYLAA 21 - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
LAYLAA 21
Authorized
STANDARD
LAYLAA 21
lupin pharma canada limited
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
0f3e0087c463ed31
Company
lupin pharma canada limited
Type
Standard
Approval Details
Approval Id
0f3e0087c463ed31
Drug Approval Canada Name
LAYLAA 21
Product Name
LAYLAA 21
Status
Marketed
Status Date
2023-11-10
Original Market Date
2023-07-06
Din
02424282
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:12.00
Atc Original
G03AA07 LEVONORGESTREL AND ESTROGEN
Atc Name
g 03 aa 07
Aig Number
0220415002
Company Name
lupin pharma canada limited
Company Address
550-1111 Rue St-Charles Ouest, Longueuil, Quebec, Canada, J4K 5G4
Active Ingredients
ETHINYL ESTRADIOL
20 MCG
LEVONORGESTREL
100 MCG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
0f3e0087c463ed31
Type
Standard
Back to Health Canada Approvals